This is a Non-interventional, Multicenter study evaluating the efficacy and safety of the combination of pegylated liposomal doxorubicin and trabectedin in routine practice in patients with recurrent partial-platinum sensitive ovarian cancer, which is held in Kazakhstan.

Inclusion Criteria:

• Age>18
• Histologically proven epithelial ovarian cancer
• ECOG 0-1
• Partially platinum sensitive relapsed ovarian cancer: platinum-free interval 6 -12 months
• With 1-2 or more cycles on trabectedin treatment at the recommended dose of 1.1mg/m2 q3w 3hr infusion in combination of PLD at 30mg/ml with appropriate pre-medication
• Prior treatment with 1 or more chemotherapy regimen

Exclusion Criteria:

• Platinum resistant disease: PFI < 6 months (progression within six months after first-line platinum-based chemotherapy)
• Unwilling or unable to have a central venous catheter
• Patients with hepatic impairment (Patients with elevated bilirubin)
• Patients with renal impairment (Patients with serum creatinine >1.5 mg/dL)
• Patients with hematologic impairment (baseline neutrophil counts of less than 1,500 cells/mm3 and platelets count of less than 100,000 cells/mm3)
• Patients with serious impaired cardiac function (patients with cardiac disease and with reduction of the QRS complex)
• AIDS-related Kaposi's sarcoma
• Lactation or pregnancy

Patients with relapsed ovarian cancer